ResMed Inc. stock gains on FY2026 growth and buyback launch
Published on 09/07/2026 at 23:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. stock (ISIN US7611521078) is trading around USD 228 as of September 7, 2026, supported by solid FY2026 revenue growth of about 8 percent and a newly launched USD 450 million accelerated share repurchase program that tightens the share count and signals confidence from management.SquawkNews
FY2026 results and buyback underpin valuation
According to a brief market update dated September 7, 2026, ResMed reported FY2026 revenue up 8 percent, pointing to mid single digit to high single digit top-line growth over the most recent fiscal year.SquawkNews For investors, that growth pace matters because it shows the medical equipment provider still expanding at a healthy rate in its core sleep and respiratory care markets.
The same update highlights that ResMed has launched a USD 450 million accelerated share repurchase program, reducing the free-float share count and supporting earnings per share over the coming quarters.SquawkNews When a company of ResMed's size commits hundreds of millions of dollars to buy back stock, it typically reflects a combination of strong cash generation and management's view that the current valuation remains attractive relative to long-term prospects.
Recent quarterly figures and margins
Market data commentary on September 7, 2026 indicates that in its latest reported quarter ResMed generated revenue of USD 1.46 billion, an increase of 8.6 percent year over year, while earnings per share came in at USD 2.95 compared with USD 2.55 in the same quarter a year earlier.MarketBeat That means quarterly EPS grew by roughly 15.7 percent, outpacing revenue growth and highlighting operating leverage in the business.
In the same quarterly release, ResMed reported a net margin of 26.94 percent and a return on equity of 25.58 percent, underscoring its position as a highly profitable medical technology company.MarketBeat For investors comparing peers in the sector, margins in the mid-20 percent range and ROE above 25 percent are attractive signals that the company is monetizing its installed base of devices and software platforms efficiently.
Dividend increase and analyst stance
ResMed has also moved to return more cash to shareholders through dividends. The company recently raised its quarterly dividend to USD 0.66 per share, up from USD 0.60 previously, implying an annualized payout of USD 2.64 and a dividend yield of about 1.2 percent at recent prices.MarketBeat The ex-dividend date for this new level was August 20, 2026, with payment scheduled for September 24, 2026, so the higher cash return is already locked in for current shareholders.MarketBeat
Despite resilient fundamentals, analyst sentiment remains mixed. One recent overview notes that ResMed stock carries a consensus Hold rating, with an average price target of USD 240.31 compared with a spot price of USD 228.25, implying modest upside of around 5.3 percent from that reference level.MarketBeat For investors, that combination of solid earnings growth, a growing dividend, and a cautious consensus suggests the market sees value but is mindful of execution and valuation risks.
Insider sale adds a risk counterpoint
A notable insider transaction provides a counter-factor to the otherwise supportive capital return story. On September 2, 2026, chairman emeritus and director Peter C. Farrell sold 970 shares of ResMed common stock at an average price of about USD 234.73 per share under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025.TipRanks After the sale, he still directly holds 51,803 shares, which keeps his personal exposure aligned with the company while nonetheless adding an element of insider selling that some investors will monitor.TipRanks
Because the transaction was executed under a Rule 10b5-1 plan, it is structured to provide an affirmative defense against insider trading allegations and is scheduled rather than opportunistic.TipRanks Even so, in combination with the buyback and dividend increase, the sale underscores how different mechanisms of capital allocation and personal portfolio management interact around the ResMed stock story.
Product and business model: sleep apnea devices
ResMed is best known for its portfolio of sleep apnea devices and related masks and accessories, which sit at the heart of its revenue base. The FY2026 revenue growth of about 8 percent indicates that demand for these devices and associated software platforms continues to expand, supported by greater awareness of sleep-disordered breathing and chronic respiratory disease.SquawkNews For investors, the installed base of connected devices forms the foundation for recurring revenue from consumables and digital health services.
ResMed Inc. stock price and market data
Recent trading data show ResMed Inc. stock changing hands at approximately USD 228.25 on the New York Stock Exchange, with that quote reported in early September 2026 and used as a reference level alongside the FY2026 results.MarketBeat At this price, and with the dividend of USD 2.64 per share on an annual basis, the implied dividend yield stands near 1.2 percent, while the consensus price target of USD 240.31 sits only modestly above the current trading range.MarketBeatMarketBeat
ResMed Inc. stock key data
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Trading venue: NYSE
- Price (as of September 7, 2026): 228.25 USD
- Market capitalization: [value] USD (as of September 7, 2026)
- Sector / Industry: Health Care / Medical Equipment
- Index membership: S&P 500
